Premium
Moxifloxacin–Tetracycline–Lansoprazole Triple Therapy for First‐Line Treatment of Helicobacter pylori Infection: A Prospective Study
Author(s) -
Taş Adnan,
Akbal Erdem,
Koçak Erdem,
Köklü Seyfettin
Publication year - 2011
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/j.1523-5378.2010.00817.x
Subject(s) - lansoprazole , tolerability , medicine , regimen , helicobacter pylori , moxifloxacin , breath test , gastroenterology , adverse effect , surgery , antibiotics , microbiology and biotechnology , biology
Abstract Aim: To document the efficacy and tolerability of 14‐day moxifloxacine–tetracycline–lansoprazole (MTL) regimens for Helicobacter pylori ( Hp ) eradication as a first‐line therapy. Method: Fifty‐six Hp‐ positive patients were enrolled. Patients were considered eligible for the study if they underwent upper gastrointestinal endoscopy, and Hp infection was diagnosed through histologic examination of antral and body bioptic samples. Primary end point of this study was to evaluate the eradication rate of 14‐day MTL regimen therapies. Hp eradication was assessed using the 13C urea breath test performed. All patients were asked to fill in a validated questionnaire to report therapy‐related side effects. Each symptom was graded from absent or present. Results: Fifty‐six patients (29 men and 27 women) were enrolled. The studied therapeutic regimens were completed by 96.4% patients. Two dropouts occurred in the MTL group because of side effects. The eradication rate in MTL regimens was 55.4%. The overall prevalence of side effects was high in the MTL group. Conclusion: The MTL regimen failed to achieve the recommended eradication rates and had higher adverse effect rate. Hence, MTL regimen does not seem to be a suitable choice as a first‐line Hp eradication therapy.